IDEAYA begins Phase 1/2 expansion study of IDE892 in MTAP-deleted pancreatic and lung cancers
Monday, July 27, 2026
IDEAYA Biosciences has initiated Part 2 of the Phase 1/2 clinical trial evaluating IDE892, its investigational methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, as a monotherapy for patients with MTAP-deleted solid tumours. The expansion phase will focus on pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).
The company said the study has progressed to the expansion stage after achieving projected therapeutic target exposures with 24-hour target EC90 coverage. Dose escalation remains ongoing, and the maximum tolerated dose has not yet been reached.
IDE892 is being developed as a potential treatment for MTAP-deleted cancers, which currently have no approved targeted therapies. MTAP deletion is estimated to occur in around 15% of all solid tumours, including 15–20% of NSCLC cases and up to 40% of PDAC cases.
The programme forms part of IDEAYA's broader precision oncology strategy targeting MTAP-deleted cancers. Alongside IDE892, the company is advancing its MAT2A inhibitor IDE397, currently in Phase 2 development, and a preclinical CDKN2A-targeted programme, with an investigational new drug (IND) application planned for the first half of 2027.
IDEAYA is also evaluating IDE892 in combination with IDE397 following the first patient being dosed in the combination study in mid-2026. In addition, the company has entered a clinical collaboration with Roche to assess IDE892 in combination with Roche's investigational pan-RAS inhibitor RG6505 for MTAP-deleted pancreatic cancer.
According to the company, IDE892 has been designed with properties intended to support combination therapies, including high selectivity for MTA-PRMT5 binding, limited brain penetration, favourable drug-like characteristics, and a low potential for cytochrome P450-mediated drug interactions. These features are expected to support future combination approaches with pan-RAS inhibitors, KRAS G12D-targeted therapies, IDE397, and IDEAYA's CDKN2A programme.
Source: prnewswire.com
